Background: Patients with adult respiratory distress syndrome (ARDS) and acute lung injury (ALI) have low concentrations of disaturated-phosphatidylcholine and surfactant protein-B in bronchoalveolar lavage fluid. No information is available on their turnover.

Objectives: To analyze disaturated-phosphatidylcholine and surfactant protein-B turnover in patients with ARDS/ALI and in human adults with normal lungs (controls).

Methods: 2H2O as precursor of disaturated-phosphatidylcholine-palmitate and 113C-Leucine as precursor of surfactant protein-B were administered intravenously to 12 patients with ARDS/ALI and to 8 controls. Disaturated-phosphatidylcholine and surfactant protein-B were isolated from serial tracheal aspirates, and their fractional synthetic rate was derived from the 2H and 13C enrichment curves, obtained by gas chromatography mass spectrometry. Disaturated-phosphatidylcholine, surfactant protein-B, and protein concentrations in tracheal aspirates were also measured.

Results: 1) Surfactant protein-B turned over at faster rate than disaturated-phosphatidylcholine both in ARDS/ALI patients and in controls. 2) In patients with ARDS/ALI the fractional synthesis rate of disaturated-phosphatidylcholine was 3.1 times higher than in controls (p < 0.01), while the fractional synthesis rate of surfactant protein-B was not different. 3) In ARDS/ALI patients the concentrations of disaturated-phosphatidylcholine and surfactant protein-B in tracheal aspirates were markedly and significantly reduced (17% and 40% of the control values respectively).

Conclusions: 1) Disaturated-phosphatidylcholine and surfactant protein-B have a different turnover both in healthy and diseased lungs. 2) In ARDS/ALI the synthesis of these two surfactant components may be differently regulated.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3072954PMC
http://dx.doi.org/10.1186/1465-9921-12-36DOI Listing

Publication Analysis

Top Keywords

surfactant protein-b
40
disaturated-phosphatidylcholine surfactant
28
protein-b turnover
12
patients ards/ali
12
tracheal aspirates
12
protein-b
10
surfactant
10
disaturated-phosphatidylcholine
9
acute lung
8
lung injury
8

Similar Publications

Surfactant protein-B (SP-B) deficiency is a lethal neonatal respiratory disease with few therapeutic options. Gene therapy using adeno-associated viruses (AAV) to deliver human cDNA (AAV-hSPB) can improve survival in a mouse model of SP-B deficiency. However, the effect of this gene therapy wanes.

View Article and Find Full Text PDF

Surfactant protein B deficiency: the RespiRare cohort.

Thorax

January 2025

Assistance Publique - Hôpitaux de Paris, Pediatric Pulmonology Department and Reference Center for Rare Lung Diseases RespiRare, Armand Trousseau Hospital, Sorbonne University, Paris, France

Article Synopsis
  • ChILD is a group of rare and severe lung diseases in children, with some cases linked to deficiencies in surfactant protein B (SP-B).
  • The RespiRare network helps to gather detailed information about the characteristics and genetic backgrounds of these patients.
  • A study involving 11 patients found that those with complete SP-B deficiency showed symptoms at birth and had a median survival of 1 month, while rarer cases with partial SP-B function might have a better chance of survival.
View Article and Find Full Text PDF

Background: The COVID-19 pandemic has led to significant concern due to its impact on human health, particularly through pneumonia-induced lung damage. Surfactant proteins A and D (SP-A and SP-D) are implicated in COVID-19 lung damage, but the role of surfactant protein B (SP-B) remains unclear.

Methods: We conducted a single-centre, prospective observational study involving 73 hospitalised COVID-19 pneumonia patients.

View Article and Find Full Text PDF

Identification of plasma proteins binding oxidized phospholipids using pull-down proteomics and OxLDL masking assay.

J Lipid Res

November 2024

Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria. Electronic address:

Article Synopsis
  • Oxidized phospholipids (OxPLs) are recognized as harmful substances that promote inflammation, highlighting the need to understand how they can be detoxified by various plasma proteins.
  • Researchers conducted pull-down-proteomic analysis to identify around 150 non-immunoglobulin proteins that specifically bind to oxidized phospholipids, particularly OxPAPC.
  • The study confirmed that these proteins, alongside known oxidized phospholipid-binding proteins, can effectively mask OxPLs, potentially influencing their recognition by the immune system.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!